Autoreactive marginal zone B cells enter the follicles and interact with CD4+ T cells in lupus-prone mice.
BACKGROUND
Marginal zone B cells have been implicated in the production of autoantibodies in murine models of lupus. It has been suggested that they contribute to lupus immunopathogenesis through their enhanced effector functions and their repertoire that is biased toward autoreactive specificities. In the B6.NZM2410.Sle.Sle2.Sle3 (B6.TC) model of lupus, the majority of marginal zone B cells are located outside the marginal zone and inside the follicles. Genetic alterations of this strain have shown a correlation between autoimmune pathogenesis and the presence of intrafollicular marginal zone B cells. This study was designed first to strengthen our original observations and to determine how the marginal zone B cells from the lupus-prone mice respond to stimulations and interact with T cells.


RESULTS
The intrafollicular location of B6.TC MZB cells starts before disease manifestations and puts MZB cells in direct contact with CD4+ T cells. Two different autoreactive B cell receptor (BCR) transgenic models showed that the expression of the Sle susceptibility loci enhances the presence of MZB cells inside the follicles. In vitro, B6.TC MZB cells were better effectors than B6 MZB cells with enhanced proliferation and antibody (Ab) production, including anti-DNA Ab, in response to stimulation with TLR ligands, immune complexes or anti-CD40. Furthermore, B6.TC MZB and CD4+ T cells showed a reciprocally enhanced activation, which indicated that their contacts inside B6.TC follicles have functional consequences that suggest an amplification loop between these two cell types.


CONCLUSIONS
These results showed that the NZM2410 susceptibility loci induce MZB cells to locate into the follicles, and that this breach of follicular exclusion occurs early in the development of the autoimmune pathogenesis. The enhanced responses to stimulation and increased effector functions of MZB cells from lupus-prone mice as compare to non-autoimmune MZB cells provide a mechanism by which the failure of MZB cell follicular exclusion contributes to the autoimmune process.
Department of Pathology, Immunology, and Laboratory Medicine, University of Florida, Gainesville, FL 32610, USA.
Zhenhai
Z
Zhou
Haitao
H
Niu
Ying-Yi
YY
Zheng
Laurence
L
Morel
D000818:Animals; D000917:Antibody Formation / Q000276:immunology; D000954:Antigens, Surface / Q000378:metabolism; D001402:B-Lymphocytes / Q000166:cytology* / Q000276:immunology; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology* / Q000276:immunology; D002450:Cell Communication / Q000276:immunology*; D002465:Cell Movement / Q000276:immunology*; D049109:Cell Proliferation; D004198:Disease Susceptibility / Q000276:immunology*; D056426:Genetic Loci / Q000235:genetics; D007075:Immunoglobulin M / Q000378:metabolism; D008180:Lupus Erythematosus, Systemic / Q000276:immunology* / Q000473:pathology*; D008213:Lymphocyte Activation / Q000276:immunology; D051379:Mice; D013154:Spleen / Q000166:cytology
D000954:Antigens, Surface; D007075:Immunoglobulin M
Int Immunol. 2010 Jun;22(6):413-9
20508253
Int Immunol. 1993 Oct;5(10):1329-41
8268138
Diabetes. 2008 Feb;57(2):395-404
18025414
J Immunol. 2005 Jun 15;174(12):7692-702
15944270
Nat Immunol. 2001 Sep;2(9):764-6
11526379
J Exp Med. 1993 May 1;177(5):1367-81
8478612
J Exp Med. 2004 Jun 21;199(12):1631-40
15197227
J Exp Med. 1999 Dec 6;190(11):1697-710
10587360
J Immunol. 2007 Jul 15;179(2):1340-52
17617627
J Immunol. 2003 Mar 1;170(5):2293-301
12594250
J Exp Med. 1998 Nov 2;188(9):1691-703
9802981
Immunol Rev. 2000 Jun;175:70-9
10933592
J Immunol. 2005 Aug 1;175(3):1440-9
16034080
J Immunol. 2007 Jun 15;178(12):7779-86
17548615
Nat Immunol. 2008 Jan;9(1):54-62
18037889
J Immunol. 2008 Mar 15;180(6):3882-8
18322196
J Exp Med. 2006 Aug 7;203(8):1985-98
16880262
J Clin Invest. 2007 Aug;117(8):2186-96
17641780
Clin Immunol. 2000 Jan;94(1):51-63
10607490
Mol Biol Rep. 1996;23(3-4):159-66
9112224
Lab Invest. 2008 Sep;88(9):1008-20
18607347
J Immunol. 2005 Apr 15;174(8):4567-78
15814678
J Immunol. 2005 Apr 15;174(8):4821-7
15814708
J Exp Med. 1995 Aug 1;182(2):559-66
7629512
Immunity. 2001 Dec;15(6):947-57
11754816
Eur J Immunol. 2007 Dec;37(12):3339-51
18034429
Proc Natl Acad Sci U S A. 2003 Oct 28;100(22):12905-10
14555759
Curr Opin Immunol. 2003 Dec;15(6):709-17
14630207
Proc Natl Acad Sci U S A. 2000 Jun 6;97(12):6670-5
10841565
J Immunol. 2004 Jan 15;172(2):803-11
14707050
J Exp Med. 2006 Feb 20;203(2):393-400
16446381
J Immunol. 2001 Aug 15;167(4):1886-90
11489967
Nature. 2002 Apr 11;416(6881):603-7
11948342
J Immunol. 1999 Jun 15;162(12):7198-207
10358166
Lab Invest. 2007 Jan;87(1):14-28
17170739
J Immunol. 2004 Apr 1;172(7):4159-66
15034028
Nat Rev Immunol. 2001 Dec;1(3):177-86
11905826
J Immunol. 2006 Sep 15;177(6):3791-8
16951340
Eur J Immunol. 1997 Sep;27(9):2366-74
9341782
Immunity. 2001 Nov;15(5):775-85
11728339
J Immunol. 1993 Apr 1;150(7):2737-45
7681079
J Immunol. 2005 Oct 1;175(7):4309-19
16177071